 |
|
|
| |
A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) in Virologically-Suppressed HIV-1 Infected Adults Harboring the NRTI Resistance Mutation M184V/I (GS-US-292-1824): Week 24 Results
|
| |
| |
17th European AIDS Conference, November 6-9, 2019, Basel
Reported by Jules Levin
Perez-Valero I1, LlibreJM2, LazzarinA3,Di PerriG4, Pulido F5, Molina JM6, EsserS7, Margot N8, Shao Y8, PiontkowskyD8, Das M8, McNichollIR8, HaubrichR8
1Unidad VIH -Hospital UniversitarioLa Paz, Madrid, Spain; 2Fundación Luchacontra el SIDA, Barcelona, Spain; 3Fondazione IRCCS San Raffaele del Monte Tabor, Milan, Italy; 4Dipartimento di MalattieInfettivee Tropicali, Turin, Italy;
5Unidad VIH, Hospital Universitario12 de Octubre, imas12, UCM, Madrid, Spain; 6Department of Infectious Diseases, Saint-Louis Hospital and University of Paris, Paris, France; 7Universitatsklinikum Essen, Essen, Germany; 8Gilead Sciences, Foster City, CA, USA
link to NATAP EACS Reports - 17th European AIDS Conference
November 6-9, 2019
Basel
Long-term Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in ART-Naïve Adults - (11/12/19)
Sustained Viral Suppression among Participants with Pre-existing M184V/I Who Switched to Bictegravir/Emtricitabine/TenofovirAlafenamide - (11/12/19)
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials - (11/07/19)
Gilead's Biktarvy Maintained High Efficacy With No Cases of Treatment-Emergent Resistance Through Three Years in Phase 3 HIV Clinical Trials - (11/06/19)
Switching to Bictegravir/Emtricitabine/TenofovirAlafenamide(B/F/TAF) in Adults Aged ≥ 65 Years: Week 48 Results from a Phase 3b, Open-Label Trial (GS-US-380-4449) - (11/12/19)
Safety and Efficacy of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People With HIV Aged 50 Years and Older - (11/12/19)
|
| |
|
|
|
|
|
